WO1996033233A1 - Copolymeres en blocs heterotelecheliques et procede de production - Google Patents
Copolymeres en blocs heterotelecheliques et procede de production Download PDFInfo
- Publication number
- WO1996033233A1 WO1996033233A1 PCT/JP1996/001057 JP9601057W WO9633233A1 WO 1996033233 A1 WO1996033233 A1 WO 1996033233A1 JP 9601057 W JP9601057 W JP 9601057W WO 9633233 A1 WO9633233 A1 WO 9633233A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- integer
- block copolymer
- formula
- polymer
- heterotelechelic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- C08G63/08—Lactones or lactides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
- C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
- C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
- C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3324—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S525/00—Synthetic resins or natural rubbers -- part of the class 520 series
- Y10S525/922—Polyepoxide polymer having been reacted to yield terminal ethylenic unsaturation
Definitions
- the present invention relates to a heterotelechelic block copolymer and a method for producing the same.
- the present invention relates to a heterotelechelic block copolymer having different functional groups at both ends, a method for producing the same, and use of the same in a polymer micelle. More specifically, the present invention discloses a polymer having mutually different functional groups at both ends, a polyethylene oxide as a hydrophilic segment in the main chain, and a polyester as a hydrophobic segment.
- the term polymer as used in the present invention is used in a concept including an oligomer.
- Polymer micelles or nanospheres composed of hydrophilic / hydrophobic block copolymers obtained by mixing a hydrophilic polymer such as polyethylene oxide with other hydrophobic polymers at the molecular level are used as drug carrier. Is attracting attention. Preparation of polymer micelles and nanospheres is achieved by a hydrophilic Z hydrophobic block copolymer in which a hydrophilic polymer and a hydrophobic polymer are bonded at the molecular level.
- the conventional method for producing a hydrophilic / hydrophobic block copolymer has a limitation in introducing a terminal functional group, and a block copolymer having a limited functional group such as a methoxy or hydroxy group has been proposed. It's just In particular, if an arbitrary reactive functional group can be successfully introduced into the micelle surface at an arbitrary ratio, it can be used for in vivo targeting of drugs and the like. It would be possible to provide functional polymeric micelles that could be used to advantage.
- an object of the present invention is to provide a block copolymer having mutually different functional groups at both ends as a multifunctional polymer capable of forming a polymer micelle.
- the present inventors have utilized an alkylene derivative having a certain aldehyde group and a hydroxyl group as an initiator for living polymerization, and polymerized ethylene oxide and lactide or lactone as monomers. It has been found that it is possible to easily provide a block copolymer having an optional aldehyde group and various functional groups at the other end.
- the block copolymer thus obtained formed extremely stable polymer micelles in an aqueous solvent.
- a heterotelechelic block copolymer represented by the following formula (I) and having mutually different functional groups at both ends of the molecule.
- R 1 and R 2 independently represent C 10 alkoxy, aryloxy or aryl-C, -3 alkyloxy, or
- R 1 and R 2 together may be substituted by C 6 alkyl.
- L represents the formula: CH— 0— C— ⁇ — or ⁇ ⁇ CH 2 ⁇ ⁇ ,
- R 3 and R 4 are independently a hydrogen atom, Alkyl, aryl or aryl- 3 alkyl, r is an integer from 2 to 5, m is an integer from 2 to: L 0.000, n is an integer from 2 to: I 0,000,
- Z is, when q is 0, a hydrogen atom, an alkaryl metal, acetyl, acryloyl, methacryloyl, cinnamyl, P-toluenesulfonyl, 2-mercaptopropionyl or 2-aminopropionyl, or aryl. or represents vinylbenzyl, when q is an integer of 1 to 20, C iota-beta alkoxycarbonyl, a carboxy Kin Le mercapto or Amino.
- a method for producing a block copolymer represented by the above formula (I) includes the following steps.
- R 1 — 1 and R 2 — 1 independently represent C 10 alkoxy, or R 1 — 1 and R 2 — 1 are taken together and substituted with de.
- M represents metal alloy
- the compound represented by is produced.
- Step (2) converting the compound represented by the formula (II) into a compound represented by the formula ( ⁇ —b)
- R 3 and R 4 independently represent a hydrogen atom, C 1 () alkyl, aryl or aryl-C, -3 alkyl, and r represents an integer of 2 to 5) React with lactide or lactone to obtain the formula R 3 R 4
- the living polymer of the present invention (included in the polymer of the formula (I)) which can be used as an intermediate material for extending any polymer segment is provided.
- the present invention has a protected aldehyde group or aldehyde group at the ⁇ -terminal of the molecule and a hydroxyl group at the ⁇ -terminal.
- Light block copolymers can be obtained.
- Step (4) A block copolymer having a protected aldehyde group at the ⁇ -terminal of the formula (V)
- block copolymer of the present invention having respective functional groups other than hydrogen groups at the ⁇ -terminus of the molecule.
- Step (5) The P-toluenesulfonate obtained in step (4) (i) is a block copolymer having another functional group (for example, mercapto or amine) at the ⁇ -terminal by transesterification or the like.
- the block copolymer having an aldehyde protecting group or a carboxyl protecting group obtained through the above steps can be subjected to a hydrolysis reaction to give either one of the protecting groups or all the protecting groups.
- the block copolymer of the present invention from which all of the protecting groups have been eliminated can be provided.
- a polymer micelle obtainable by using the block copolymer represented by the formula (I). Is done.
- heterotelechelic polymers of the invention can be used as precursors for the production of further polymers, and these polymers have biocompatibility, as can be understood from their constituents, High bioavailability can be expected. Therefore, it can be used, for example, as a material directly applied to a living body, for example, a carrier material for supporting a drug, and, in particular, according to the third aspect of the present invention, provides a polymer micelle that is extremely stable in an aqueous solvent. since it brief description of the c drawings are also useful as targeting pharmaceutical carrier in vivo
- FIG. 1 is a gel permeation chromatogram of an acetal ⁇ -terminal hydroxy ⁇ -terminal polyesteroxide polylactide block copolymer (sample of Example 1).
- FIG. 2 is a proton nuclear magnetic resonance spectrum of an acetal ⁇ -terminal Z hydroxy ⁇ -terminal polyethylene oxide / polylactide block copolymer (sample of Example 1).
- FIG. 3 is a proton nuclear magnetic resonance spectrum of an acetal ⁇ -terminal hydroxy ⁇ -terminal polyethylene oxide poly (5-valerolactone) block copolymer (sample of Example 3).
- Figure 4 shows aldehyde tr-terminal hydroxy and ⁇ -terminal polyethyleneoxy.
- 3 is a proton nuclear magnetic resonance spectrum of dovoractide block copolymer (sample of Example 4).
- FIG. 5 is a carbon nuclear magnetic resonance spectrum of an acetal ⁇ -terminal methacryloyl ⁇ -terminal polyethylene oxide polylactide block copolymer (sample of Example 5).
- FIG. 6 is a carbon nuclear magnetic resonance spectrum of an acetal ⁇ -terminal allyl ⁇ -terminal polyethylene oxide / polylactide block copolymer (sample of Example 6).
- FIG. 7 is a carbon nuclear magnetic resonance spectrum of an acetal ⁇ -terminal ⁇ para-toluenesulfonyl ⁇ -terminal polyethylene oxide borylactide block copolymer (sample of Example 6).
- Figure 8 shows the particle size distribution of polymer micelles in an aqueous solution of an aldehyde-terminal ⁇ hydroxy ⁇ -terminal polyethylene oxide ⁇ borylactide block copolymer (sample of Example 4) by dynamic laser single light scattering.
- FIG. 9 is a diagram showing measured results.
- the alkyl part and the alkyl of the alkoxy in the present invention mean a linear or branched alkyl group. Therefore, as the alkyl moiety of C, 0 alkoxy or Ci- 10 alkyl in the formulas ( ⁇ ) and (III-a), methyl, ethyl, propyl, iso-propyl, butyl, se-butyl, tert. -Butyl, pentyl, iso-pentyl, hexyl, 2-methylpentyl, 3-methylpentyl, octyl, 2-ethylhexyl, decyl and 4-propylpentyl. Of these, R 1 and
- the alkyl moiety of the alkoxy represented by R 2 is preferably d-6 alkyl, Preferably, d-3 alkyl is used.
- R 1 and particularly preferred as the main butoxy as alkoxy refers to R 2, ethoxy, Purobokishi, isopropoxy Ru mentioned.
- R 1 and R 2 are preferably aryl, especially phenyl, or aryl-d-3alkyl, especially benzyl or phenyl. These groups may be the same or different, but are preferably the same group. Further, R 1 and R 2 together form an ethylenedioxy which may be substituted with C- ⁇ - alkyl.
- P in the formula (I) represents an integer of 1 to 5, but p in the formula (I)
- CH—CH 2 —0— segment is derived from the p-polymerization initiator (see formula (II)) in the production method of the present invention, this segment is integrated with dimethoxy methoxy, 2 , 2-Dimethoxyethoxykin,
- a hydrogen atom, C, - 1 0 alkyl, Ariru or Ariru - d - 3 may be any of alkyl, but bioavailability From the viewpoint, a hydrogen atom (derived from glutaric acid) and methyl (derived from lactic acid) are preferred.
- m in the formula (I) can theoretically be an arbitrary number of m by adjusting the ratio of the amount of ethylene oxide (monomer) to the polymerization initiator.
- m may have any integer from 2 to 100,000.
- This segment imparts hydrophilicity to the block copolymer of the present invention.
- M is preferably an integer of 10 or more.
- m is set to an integer of 500 or less, preferably 200 or less, in that the molecular weight distribution of this segment is narrow and easy to adjust, and a block copolymer excellent in bioavailability can be provided. Choose.
- n which defines the molecular weight of the polyester segment of the formula (I) is, as can be understood from the fact that this segment mainly imparts hydrophobicity to the block copolymer of the present invention, the group of R 3 and R 4
- the optimal number of n fluctuates according to the nature.
- any number of m can be provided to the polymerization method of the present invention, for example, similarly to the case of the polyethylene oxide segment. Therefore, the number of m is not limited, but is usually 2 to 100,000.
- m be an integer of 100.
- the ⁇ ecH 2 > ⁇ ⁇ z segment of the formula (I) mainly specifies the ⁇ -terminal functional group (or reactive group) of the block copolymer of the present invention.
- q is 0 (ie, when Z is directly bonded to the ⁇ -position oxygen atom of the polyester segment)
- it can be an alkali metal first.
- the polymer of the present invention can be a living polymer. Therefore, since the polymer of the present invention can act as an initiator for further living polymerization, it is also useful as a precursor of various other polymers.
- examples of the alkali metal include sodium, potassium and cesium.
- ⁇ represents a hydrogen atom ( ⁇ terminal is a hydroxyl group)
- this hydroxyl group can be converted to another functional group by various reactions, for example, esterification and etherification. Therefore, when q is 0, Z is acetyl (one COCH 3 ), acryloyl
- q is 1-2 integer 0, if preferably 1 to 4, particularly preferably 2 integer, "fC H 2)
- q Z are together, for example, d-e alkoxy (eg example, main butoxy , Ethoxy, propoxy) carbonylmethyl, -ethyl or -propyl, or 2-aminoethyl, carboquinlmethyl, -ethyl or -propyl.
- Z H3 ( S H0) 303 OA _ ⁇ ? ⁇ ?-0 ZZ 0 Z HD 6 H3 0 ⁇ ⁇ 3 ⁇ ⁇ 3 9
- Z H3 H303 OA -H ⁇ OH?-08Z Z 0 ⁇ ⁇ 0 ⁇ ⁇ 3 0 ⁇ ⁇ 3 ⁇ ⁇ 3 S
- ⁇ 3 ( ⁇ ⁇ 3) 303 OS ⁇ Z HD - 001 0 ⁇ ⁇ 0 ⁇ ⁇ 3 0 ⁇ ⁇ 3 ⁇ ⁇ 3 ⁇
- Z H3 H303 OS H Z HD-001 0 Z H3 S H3 0 ⁇ ⁇ 3 ⁇ ⁇ 3 9 ⁇
- the alkali metal acetal protected alkoxide (A) is reacted with ethylene oxide to obtain a compound (B) having a polyethylene oxide segment added thereto.
- Compound (A) is used to convert acetal-protected alcohol into a metalating agent. And treated with alkaline metal such as sodium phosphate, organic metal such as sodium naphthalene, potassium naphthagen, cumyl potassium, cumyl cesium, and metal hydrogen such as sodium hydride, potassium hydride, etc. Can be obtained.
- the above-mentioned reaction from (A) to (B) may be carried out in the absence of a solvent or preferably in an anhydrous nonprotonic solvent at a wide range of temperatures, for example, 150 to 300 ° C., preferably 1 ° C. It can be carried out at 0 ° C to 60 ° C, conveniently at room temperature (20 to 30 ° C).
- the reaction may be performed under elevated or reduced pressure.
- the solvent used include, but are not limited to, benzene, toluene, xylene, tetrahydrofuran, dioxane, and acetonitrile.
- reaction vessel is not particularly limited, for example, a round bottom flask, an o-trave, a pressure tight tube and the like are used. It is preferable that the inside of the reaction vessel can be shielded from outside air, and it is more preferable that the inside of the reaction vessel can be filled with an inert gas.
- concentration of the reaction solution is preferably 0.1 to 95% by weight, more preferably 1 to 80% by weight, and most preferably 3 to 10% by weight.
- the reaction mixture containing (B) is reacted with lactide or lactone to obtain a living block copolymer (C) in which a polyester segment is added via the ⁇ -terminal hydroxyl group of polyethylene oxide.
- This reaction condition can be almost the same as the reaction to the above ( ⁇ ) or ( ⁇ ).
- the lactides and lactones which can be used are those which can form the chains defined for R 3 and for L in formula (I).
- Preferred lactides include, but are not limited to, lactic acid lactide and glycolic acid lactide.
- available lactones are 5-propiolactone, 7- Petrolactone, 5-valerolactone and ⁇ -force prolacton. From the viewpoint of ease of reaction, 7-butyrolactone and ⁇ 5-valerolactone are preferred.
- the ratio of the polymerization initiator to ethylene oxide or lactide or lactone used in each of the above steps is 1: 1 to 1: 10,000, more preferably 1: 5 to 1: 10,000, respectively, in a molar ratio. More preferably, it ranges from 1:10 to 200 to 1:50 to 200.
- each segment not only can adjust the molecular weight according to the amount of the monomer used for the initiator, but also has a very narrow molecular weight distribution, monodispersity or monomodal distribution of each segment produced.
- Block copolymers can be provided.
- the living polymer thus obtained (C) itself is included in the polymer of the present invention, but the alcoholate of (C) is partially hydrolyzed under (i) mild conditions (just by adding water).
- (Ii) has an aldehyde group at the ⁇ -terminus
- (ii) has an aldehyde group at the ⁇ -terminus by treating (C) under conditions that allow simultaneous hydrolysis of the acetal. It can be converted to a polymer (D ') having a hydroxyl group.
- organic acid (i) a reactive derivative of an organic acid such as an acid anhydride or an acid halide is preferably used.
- ⁇ -tonolene sulfonyl compound (F) may be used as an electrophile, for example, an electrophile such as sodium thioacetate, potassium thioacetate, and potassium hydrogen sulfide
- an electrophile such as sodium thioacetate, potassium thioacetate, and potassium hydrogen sulfide
- hydrolysis of (D) may be carried out by using ⁇ -(2-bromoethyl) phthalimid, ⁇ - (3-bromopropyl) phthalimid, 1- By reacting bromo-2- (benzeneamino) ethane, benzyl ⁇ - (2-bromoethyl) carbamate, etc., and then treating with alkali or acid, the groups R 1 and R 2 are deprotected and simultaneously ⁇ - By hydrolyzing the terminal imid bond, a polymer having an amino group at the ⁇ -terminal can be obtained.
- the non-terminal aldehyde due to the deprotection of the radicals R 1 and R 2 of the polymers (D), ( ⁇ ), (F) and (G) is converted according to the above conversion of (C) to (D ′). It can be carried out. Polymer is recovered from the reaction solution by its own solvent precipitation method, gel separation chromatography, dialysis, ultra extinction, etc. be able to.
- heterotelechelic block copolymers represented by the formula (I) of the present invention can be obtained.
- the resulting polymers (excluding living polymers) can form extremely stable polymeric micelles in aqueous solvents.
- This polymer micelle can be prepared, for example, by subjecting a polymer solution or suspension to a heating treatment, an ultrasonic irradiation treatment, or an organic solvent treatment alone or in combination.
- the warming treatment involves dispersing or dissolving one or more mixtures of the block copolymers of the present invention in water at a temperature of 30 ° C to 100 ° C, more preferably at a temperature of 30 ° C to 50 ° C.
- Ultrasonic irradiation involves dispersing one or more mixtures of block copolymers in water and treating for 1 second to 24 hours in the range of 1 W to 20 W, preferably 3 to 24 hours in the range of 1 W to 3 W. Do time.
- Organic solvent treatment involves dissolving one or more mixtures of block copolymers in an organic solvent, dispersing the solution in water, and evaporating the organic solvent.
- organic solvent chloroform, benzene, toluene, methylene chloride and the like can be used.
- the polymer micelle of the present invention can also be prepared by dissolving in methanol, ethanol, tetrahydrofuran, dioxane, dimethylsulfoxide, dimethylformamide or the like, and then dialyzing against an aqueous solvent.
- the molecular weight cut-off of the dialysis membrane used for dialysis is not limited because the optimum molecular weight varies depending on the molecular weight of the target block copolymer, but it is generally not more than 1, 000, 0000, preferably 5, 000 to 200, 000 are used.
- Water or a buffer solution can be used as the water-soluble solvent, and the ratio of the aqueous solvent to the organic solvent used for dialysis is generally 1 to 1000 times, preferably 10 to 100 times. .
- the temperature is not particularly limited, and generally, it is preferably 5 to 25 ° C.
- the polymer micelles of the present invention thus obtained generally have an extremely low critical micelle concentration of 4 to 12 mg ⁇ , and are compared with low molecular micelles such as liposomes widely studied as drug carriers in aqueous solvents. It is extremely stable. This indicates that, for example, when the polymer micelle of the present invention is administered to blood, the half-life in blood can be expected to be significantly increased, and the polymer of the present invention has excellent properties as a drug carrier. It can be said that it has.
- the present invention will be described more specifically with reference to specific examples, but it is not intended to limit the present invention to these examples.
- Proton nuclear magnetic resonance spectroscopy of the obtained polymer in deuterated methylform showed that the polymer had both polyethylene oxide (PEO) and polylactide (PL) units and an ⁇ -terminal
- the oligomer was a heterotelechelic oligomer having an acetal group and a hydroquine group at the ⁇ -terminal quantitatively (see Fig. 2).
- the number average molecular weight of each segment of the block polymer determined from the integral ratio of this spectrum was about 8800 for the polymer and about 7000 for the PL.
- Proton nuclear magnetic resonance spectroscopy of the obtained polymer in deuterated methylform showed that the polymer had both polyethylene oxide (PEO) and polylactide (PL) units and an ⁇ -terminal Acetal group, ⁇ -end It was confirmed that the oligomer was a heterotelechelic oligomer quantitatively having a hydroxy group at the end.
- the number average molecular weight of each segment of the block polymer determined from the integral ratio of this spectrum was about 5400 for PEO and about 6600 for PL.
- Proton nuclear magnetic resonance spectroscopy of the obtained polymer in deuterated methylform revealed that the polymer contained both polyethylene oxide (PEO) and poly (5-valerolactone) (PVL) units. It was confirmed to be a heterotelechelic oligomer having an acetal group at the ⁇ -terminal and a hydroxyl group at the ⁇ -terminal quantitatively (see FIG. 3).
- the number average molecular weight of each segment of the block polymer obtained from the integral ratio of the spectrum was about 8800 for P0 and about 5200 for PVL.
- the block copolymer sample obtained in Example 2 1. 50 ml of 2.Omol / L-HCl was added to 5 Oml of methanol in which Og was dissolved, and the mixture was stirred at room temperature for 1 hour. This solution was neutralized with an aqueous NaOH solution, dialyzed against a 20-fold amount of water for 4 hours (fraction molecular weight: 1,000), and purified by freeze-drying. The yield is 0.85g (85%). It was confirmed by gel permeation chromatography that the molecular weight of the polymer obtained did not change from that before the reaction.
- the block copolymer sample obtained in Example 2 1. 20 ml of pyridine and 1.0 g of methacrylic anhydride were added to 20 ml of a form in which Og was dissolved, and the mixture was stirred at room temperature for 24 hours. This solution was neutralized with an aqueous hydrochloric acid solution and washed. The black form phase was poured into cold propanol to precipitate the polymer. The precipitate obtained by centrifugation was purified by freeze-drying from benzene. The yield is 0.8g (80%). It was confirmed that the molecular weight of the polymer obtained by gel permeation chromatography did not change from that before the reaction.
- Block copolymer sample obtained in Example 2 1. To 20 ml of tetrahydrofuran in which Og is dissolved, 2 ml of a solution of potassium naphthalene in 0. SmolZL-tetrahydrofuran and 5 ml of aryl bromide are added, and the mixture is stirred at room temperature for 4 hours. Was. The resulting reaction was poured into cold propanol to precipitate the polymer. The precipitate obtained by centrifugation was purified by freeze-drying from benzene. The yield is 0.98g (98%). Gel permeation chromatography It was confirmed that the molecular weight of the polymer obtained by the method did not change from that before the reaction.
- the block copolymer sample obtained in Example 4 1.To 20 ml of tetrahydrofuran in which Og was dissolved, 2 ml of a 0.5 mol ZL-tetrahydrofuran solution of potassium nitrate and 5 g of paratoluenesulfonyl chloride were added. Allowed to stir for hours. The resulting reaction was poured into cold propanol to precipitate the polymer. Lyophilize the precipitate obtained by centrifugation from benzene Purified. The yield is 0.95g (95%). It was confirmed that the molecular weight of the polymer obtained by gel permeation chromatography did not change from that before the reaction.
- Example 2 Dissolve 5 Omg of the block copolymer sample obtained in Example 2 in water or a suitable buffer solution to 0.01 to 0.1% (w / V). The formation of micelles in these solutions was confirmed by particle size distribution measurement using dynamic light scattering. As a result, the formation of a single favorable molecular micelle having an average particle size of 3 Onm was confirmed (see Fig. 8). The critical micelle concentration of this polymer micelle was 1 OiigZ.
- the polymer has both polyethylene oxide (PEO) and polylactide (PL) units, and has an ⁇ -terminal It was confirmed that this was a heterotelechelic oligomer having an acetal group and a hydroxyl group at the ⁇ -terminal quantitatively.
- the number average molecular weight of each segment of the block polymer determined from the integral ratio of the spectrum was 5800 for ⁇ and 5100 for PL.
- 0.1N hydrochloric acid was added dropwise to 10 ml of the micelle solution obtained in Example 9 to adjust the pH to 2, and the mixture was stirred at room temperature for 2 hours.
- the mixture was neutralized with 0.1 N aqueous sodium hydroxide solution and dialyzed against water with a dialysis membrane having a molecular weight cutoff of 12000 to 14000 for 24 hours (water exchange every 2 L, 2, 5, and 8 hours). From the dynamic light scattering measurement of the obtained solution, polymer micelles having an average particle size of 4 ⁇ were purified. This glare micelle concentration was SingZL.
- the micelle solution was freeze-dried, dissolved in deuterated dimethyl sulfokind, and then subjected to NMR measurement.As a result, the signals derived from the acetal groups at 1.2 ⁇ and 4.6 ppra almost completely disappeared, and 2.7 ppm (t) and At 8 ppm (s), signals derived from carbonylmethylene and aldehyde hydrogen appeared, respectively. From the signal area ratio, 95% of the acetal was hydrolyzed to aldehyde.
- PE OZP LA block polymer (number average molecular weight of number average segment PEO: 4500; PLA; 13000) synthesized in the same manner as in Example 1 was dissolved in 4 Oml of dimethylacetamide, and the molecular weight cutoff was 12, Dialysis was performed against water with a dialysis membrane of 000-14,000 for 24 hours (water exchange every 2 L, 2, 5, 8 hours). From the dynamic light scattering measurement of the obtained solution, polymer micelles having an average particle size of 30 nm were purified. The critical micelle concentration is 4 / L
- a heterotelechelic oligomer or polymer having different functional groups at both ends of the molecule and having a hydrophilic segment and a hydrophobic segment in the main chain.
- These oligomers or polymers are expected to be more bioavailable than their constituents.
- these oligomers or polymers can form very stable polymeric micelles in aqueous solvents.
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP53161996A JP3855279B2 (ja) | 1995-04-19 | 1996-04-18 | ヘテロテレケリックブロックコポリマーおよびその製造方法 |
US08/930,898 US5925720A (en) | 1995-04-19 | 1996-04-18 | Heterotelechelic block copolymers and process for producing the same |
AT96910195T ATE226603T1 (de) | 1995-04-19 | 1996-04-18 | Heterotelechelische blockcopolymere und verfahren zu deren herstellung |
AU53468/96A AU5346896A (en) | 1995-04-19 | 1996-04-18 | Heterotelechelic block copolymers and process for producing the same |
NZ305471A NZ305471A (en) | 1995-04-19 | 1996-04-18 | Use of heterotelechelic block copolymers as carriers for medicaments |
DE69624475T DE69624475T2 (de) | 1995-04-19 | 1996-04-18 | Heterotelechelische blockcopolymere und verfahren zu deren herstellung |
SI9620067A SI9620067A (sl) | 1995-04-19 | 1996-04-18 | Heteroteleheličen blok-kopolimer in postopek za njegovo proizvodnjo |
EP96910195A EP0822217B1 (en) | 1995-04-19 | 1996-04-18 | Heterotelechelic block copolymers and process for producing the same |
BR9608330-1A BR9608330A (pt) | 1995-04-19 | 1996-04-18 | Copolìmero em bloco heterotelequélico e um método para a produção do mesmo. |
NO19974678A NO314762B1 (no) | 1995-04-19 | 1997-10-10 | Heterotelechelisk blokk-kopolymer og en fremgangsmåte for fremstilling derav og anvendelse i höymolekyl¶re miceller |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9392895 | 1995-04-19 | ||
JP7/93928 | 1995-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996033233A1 true WO1996033233A1 (fr) | 1996-10-24 |
Family
ID=14096103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/001057 WO1996033233A1 (fr) | 1995-04-19 | 1996-04-18 | Copolymeres en blocs heterotelecheliques et procede de production |
Country Status (16)
Country | Link |
---|---|
US (1) | US5925720A (ja) |
EP (1) | EP0822217B1 (ja) |
JP (1) | JP3855279B2 (ja) |
KR (1) | KR19990007861A (ja) |
CN (1) | CN1085987C (ja) |
AT (1) | ATE226603T1 (ja) |
AU (1) | AU5346896A (ja) |
BR (1) | BR9608330A (ja) |
CA (1) | CA2218495A1 (ja) |
DE (1) | DE69624475T2 (ja) |
HU (1) | HUP9801633A3 (ja) |
NO (1) | NO314762B1 (ja) |
NZ (1) | NZ305471A (ja) |
RU (1) | RU2169742C2 (ja) |
SI (1) | SI9620067A (ja) |
WO (1) | WO1996033233A1 (ja) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999018998A3 (en) * | 1997-10-09 | 1999-07-22 | Univ Liverpool | Delivery system |
WO2001055722A1 (fr) * | 2000-01-26 | 2001-08-02 | Kazunori Kataoka | Detection d'une cible biologique |
WO2001086301A1 (fr) * | 2000-05-11 | 2001-11-15 | Center For Advanced Science And Technology Incubation, Ltd. | Composition polymère pour former la surface d'un biocapteur |
JP2003026566A (ja) * | 2001-07-13 | 2003-01-29 | Nano Career Kk | 薬物含有高分子ミセルの凍結乾燥用組成物およびその凍結乾燥製剤 |
WO2003076933A1 (fr) * | 2002-03-11 | 2003-09-18 | Toudai Tlo, Ltd. | Surface en poly(ethylene oxyde) a structure de type pinceau presentant une densite elevee |
WO2005073370A1 (ja) * | 2004-01-31 | 2005-08-11 | Transparent Inc. | 酵素複合体 |
WO2006095668A1 (ja) * | 2005-03-09 | 2006-09-14 | Toray Industries, Inc. | 微粒子および医薬品組成物 |
WO2007102608A1 (ja) * | 2006-03-06 | 2007-09-13 | Nanocarrier Co., Ltd. | 疎水性化合物の安定化剤 |
WO2007126110A1 (ja) | 2006-04-24 | 2007-11-08 | Nanocarrier Co., Ltd. | 低分子薬物内包ポリマーミセルの製造方法 |
WO2008010341A1 (fr) | 2006-07-18 | 2008-01-24 | Nanocarrier Co., Ltd. | Polypeptide physiologiquement actif, micelle de polymère ayant une protéine enfermée dans celle-ci, et procédé d'obtention de la micelle de polymère |
WO2008062909A1 (fr) | 2006-11-22 | 2008-05-29 | The University Of Tokyo | Support d'arnsi sensible à l'environnement utilisant une micelle polymérique à pont disulfure |
EP1939280A1 (en) | 2001-07-26 | 2008-07-02 | Transparent Inc. | Cultured cell construct which contains spheroids of cultured animal cells and the use thereof |
WO2009133968A1 (ja) | 2008-04-30 | 2009-11-05 | 国立大学法人東京大学 | 電荷変換型三元系ポリプレックス |
WO2009157279A1 (ja) | 2008-06-24 | 2009-12-30 | ナノキャリア株式会社 | シスプラチン配位化合物の液体組成物 |
WO2009157561A1 (ja) | 2008-06-26 | 2009-12-30 | 独立行政法人科学技術振興機構 | Mri造影能を有する重合体-金属錯体複合体、並びにそれを用いたmri造影用及び/又は抗腫瘍用組成物 |
WO2011043980A1 (en) | 2009-10-07 | 2011-04-14 | Sanford Burnham Medical Research Institute | Methods and compositions related to clot-binding lipid compounds |
WO2011096558A1 (ja) | 2010-02-05 | 2011-08-11 | ナノキャリア株式会社 | 易崩壊型ポリマーミセル組成物 |
WO2011127405A1 (en) | 2010-04-08 | 2011-10-13 | Sanford-Burnham Medical Research Institute | Methods and compositions for enhanced delivery of compounds |
WO2011145745A1 (ja) | 2010-05-21 | 2011-11-24 | 独立行政法人科学技術振興機構 | 物質内包ベシクル及びその製造方法 |
US8075909B2 (en) | 2007-09-04 | 2011-12-13 | University Of Florida Research Foundation, Incorporated | Contact lens based bioactive agent delivery system |
WO2012005376A1 (ja) | 2010-07-09 | 2012-01-12 | 国立大学法人 東京大学 | 核酸送達用組成物及び担体組成物、それを用いた医薬組成物、並びに核酸送達方法 |
EP2474310A1 (en) | 2005-06-09 | 2012-07-11 | NanoCarrier Co., Ltd. | Method for producing polymerized coordination compounds of platinum complex |
WO2012118778A1 (en) | 2011-02-28 | 2012-09-07 | Sanford-Burnham Medical Research Institute | Truncated car peptides and methods and compositions using truncated car peptides |
JP2013116933A (ja) * | 2011-12-01 | 2013-06-13 | Mitsubishi Rayon Co Ltd | ポリエステル(メタ)アクリレート、およびその製造方法 |
US8592385B2 (en) | 2006-03-01 | 2013-11-26 | The University Of Tokyo | Polymer micelle complex including nucleic acid |
WO2014133172A1 (ja) | 2013-03-01 | 2014-09-04 | 独立行政法人科学技術振興機構 | 物質内包ベシクル及びその製造方法 |
WO2014185504A1 (ja) | 2013-05-17 | 2014-11-20 | ナノキャリア株式会社 | ポリマーミセル医薬組成物 |
WO2015016382A1 (en) | 2013-07-31 | 2015-02-05 | Ricoh Company, Limited | Imaging apparatus |
WO2015020026A1 (ja) | 2013-08-06 | 2015-02-12 | 独立行政法人科学技術振興機構 | 核酸内包高分子ミセル複合体及びその製造方法 |
WO2015025983A1 (ja) | 2013-08-23 | 2015-02-26 | 国立大学法人東京大学 | 高分子ナノ粒子複合体、及びそれを含むmri造影用組成物 |
WO2015104739A1 (ja) | 2014-01-10 | 2015-07-16 | Jfeスチール株式会社 | 極厚肉油井管用ねじ継手 |
WO2015163195A1 (ja) * | 2014-04-25 | 2015-10-29 | 日産化学工業株式会社 | レジスト下層膜形成組成物及びそれを用いたレジストパターンの形成方法 |
WO2018204392A1 (en) | 2017-05-02 | 2018-11-08 | Stanford Burnham Prebys Medical Discovery Institute | Tumor associated monocyte/macrophage binding peptide and methods of use thereof |
US10179801B2 (en) | 2011-08-26 | 2019-01-15 | Sanford-Burnham Medical Research Institute | Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides |
US10500246B2 (en) | 2015-06-25 | 2019-12-10 | Sanford Burnham Prebys Medical Discovery Institute | Compositions for delivery to and treatment of atherosclerotic plaques |
WO2020161602A1 (en) | 2019-02-04 | 2020-08-13 | University Of Tartu | Bi-specific extracellular matrix binding peptides and methods of use thereof |
WO2023068347A1 (ja) * | 2021-10-22 | 2023-04-27 | 株式会社クラレ | β-メチル-δ-バレロラクトン系重合体の製造方法 |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001048978A (ja) * | 1999-08-04 | 2001-02-20 | Nano Career Kk | オキサゾリン由来のポリマーセグメントを有するブロックコポリマー |
US6790228B2 (en) * | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US7682647B2 (en) * | 1999-09-03 | 2010-03-23 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of a drug eluting implantable medical device |
CA2389917A1 (en) | 1999-11-04 | 2001-05-10 | Kazunori Kataoka | A polymer micelle as monolayer or layer-laminated surface |
JP2001131271A (ja) * | 1999-11-04 | 2001-05-15 | Kazunori Kataoka | ポリマーミセルの層の積層した表面およびその作成方法 |
US7682648B1 (en) | 2000-05-31 | 2010-03-23 | Advanced Cardiovascular Systems, Inc. | Methods for forming polymeric coatings on stents |
US6451373B1 (en) | 2000-08-04 | 2002-09-17 | Advanced Cardiovascular Systems, Inc. | Method of forming a therapeutic coating onto a surface of an implantable prosthesis |
US6953560B1 (en) | 2000-09-28 | 2005-10-11 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US7807210B1 (en) | 2000-10-31 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Hemocompatible polymers on hydrophobic porous polymers |
US6824559B2 (en) * | 2000-12-22 | 2004-11-30 | Advanced Cardiovascular Systems, Inc. | Ethylene-carboxyl copolymers as drug delivery matrices |
US6663662B2 (en) * | 2000-12-28 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Diffusion barrier layer for implantable devices |
US6780424B2 (en) * | 2001-03-30 | 2004-08-24 | Charles David Claude | Controlled morphologies in polymer drug for release of drugs from polymer films |
US6712845B2 (en) * | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
US6656506B1 (en) * | 2001-05-09 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Microparticle coated medical device |
US20040171808A1 (en) * | 2001-05-30 | 2004-09-02 | Kazunori Kataoka | Method of bonding substance to be incorporated into polymer terminal |
US6881484B2 (en) * | 2001-05-30 | 2005-04-19 | Mitsubishi Kagaku Iatron, Inc. | Core-shell particle including signal-generating substance enclosed therein and process for producing the same |
US6743462B1 (en) | 2001-05-31 | 2004-06-01 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for coating implantable devices |
US7094810B2 (en) * | 2001-06-08 | 2006-08-22 | Labopharm, Inc. | pH-sensitive block copolymers for pharmaceutical compositions |
US6939564B2 (en) * | 2001-06-08 | 2005-09-06 | Labopharm, Inc. | Water-soluble stabilized self-assembled polyelectrolytes |
US6695920B1 (en) | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US8741378B1 (en) | 2001-06-27 | 2014-06-03 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device |
CA2450949C (en) * | 2001-06-28 | 2009-04-28 | John Samuel | Methods and compositions for polyene antibiotics with reduced toxicity |
US7682669B1 (en) | 2001-07-30 | 2010-03-23 | Advanced Cardiovascular Systems, Inc. | Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device |
US8303651B1 (en) | 2001-09-07 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Polymeric coating for reducing the rate of release of a therapeutic substance from a stent |
US7989018B2 (en) | 2001-09-17 | 2011-08-02 | Advanced Cardiovascular Systems, Inc. | Fluid treatment of a polymeric coating on an implantable medical device |
US7285304B1 (en) | 2003-06-25 | 2007-10-23 | Advanced Cardiovascular Systems, Inc. | Fluid treatment of a polymeric coating on an implantable medical device |
US7223282B1 (en) | 2001-09-27 | 2007-05-29 | Advanced Cardiovascular Systems, Inc. | Remote activation of an implantable device |
US6753071B1 (en) | 2001-09-27 | 2004-06-22 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
US6709514B1 (en) | 2001-12-28 | 2004-03-23 | Advanced Cardiovascular Systems, Inc. | Rotary coating apparatus for coating implantable medical devices |
US7919075B1 (en) | 2002-03-20 | 2011-04-05 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices |
WO2003082303A1 (en) * | 2002-03-29 | 2003-10-09 | Wisconsin Alumni Research Foundation | Polymeric micelle formulations of hydrophobic compounds and methods |
US7056523B1 (en) | 2002-06-21 | 2006-06-06 | Advanced Cardiovascular Systems, Inc. | Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine |
US8506617B1 (en) | 2002-06-21 | 2013-08-13 | Advanced Cardiovascular Systems, Inc. | Micronized peptide coated stent |
US7794743B2 (en) | 2002-06-21 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of making the same |
US7033602B1 (en) | 2002-06-21 | 2006-04-25 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of coating implantable medical devices |
US7217426B1 (en) | 2002-06-21 | 2007-05-15 | Advanced Cardiovascular Systems, Inc. | Coatings containing polycationic peptides for cardiovascular therapy |
US7087263B2 (en) * | 2002-10-09 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Rare limiting barriers for implantable medical devices |
US20040116360A1 (en) * | 2002-10-15 | 2004-06-17 | Kwon Glen S. | Encapsulation and deaggregation of polyene antibiotics using poly(ethylene glycol)-phospholipid micelles |
US6896965B1 (en) | 2002-11-12 | 2005-05-24 | Advanced Cardiovascular Systems, Inc. | Rate limiting barriers for implantable devices |
US6982004B1 (en) | 2002-11-26 | 2006-01-03 | Advanced Cardiovascular Systems, Inc. | Electrostatic loading of drugs on implantable medical devices |
US7758880B2 (en) | 2002-12-11 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Biocompatible polyacrylate compositions for medical applications |
US7776926B1 (en) | 2002-12-11 | 2010-08-17 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for implantable medical devices |
US7074276B1 (en) | 2002-12-12 | 2006-07-11 | Advanced Cardiovascular Systems, Inc. | Clamp mandrel fixture and a method of using the same to minimize coating defects |
US20060002968A1 (en) | 2004-06-30 | 2006-01-05 | Gordon Stewart | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders |
US7758881B2 (en) | 2004-06-30 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US8435550B2 (en) | 2002-12-16 | 2013-05-07 | Abbot Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US6926919B1 (en) | 2003-02-26 | 2005-08-09 | Advanced Cardiovascular Systems, Inc. | Method for fabricating a coating for a medical device |
US7063884B2 (en) | 2003-02-26 | 2006-06-20 | Advanced Cardiovascular Systems, Inc. | Stent coating |
US7563483B2 (en) * | 2003-02-26 | 2009-07-21 | Advanced Cardiovascular Systems Inc. | Methods for fabricating a coating for implantable medical devices |
US7279174B2 (en) | 2003-05-08 | 2007-10-09 | Advanced Cardiovascular Systems, Inc. | Stent coatings comprising hydrophilic additives |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
US7056591B1 (en) | 2003-07-30 | 2006-06-06 | Advanced Cardiovascular Systems, Inc. | Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same |
US7785512B1 (en) | 2003-07-31 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices |
US7431959B1 (en) * | 2003-07-31 | 2008-10-07 | Advanced Cardiovascular Systems Inc. | Method and system for irradiation of a drug eluting implantable medical device |
US7645474B1 (en) | 2003-07-31 | 2010-01-12 | Advanced Cardiovascular Systems, Inc. | Method and system of purifying polymers for use with implantable medical devices |
US7441513B1 (en) | 2003-09-26 | 2008-10-28 | Advanced Cardiovascular Systems, Inc. | Plasma-generated coating apparatus for medical devices and a method of coating deposition |
US7198675B2 (en) | 2003-09-30 | 2007-04-03 | Advanced Cardiovascular Systems | Stent mandrel fixture and method for selectively coating surfaces of a stent |
US7318932B2 (en) * | 2003-09-30 | 2008-01-15 | Advanced Cardiovascular Systems, Inc. | Coatings for drug delivery devices comprising hydrolitically stable adducts of poly(ethylene-co-vinyl alcohol) and methods for fabricating the same |
US7704544B2 (en) * | 2003-10-07 | 2010-04-27 | Advanced Cardiovascular Systems, Inc. | System and method for coating a tubular implantable medical device |
US7329413B1 (en) * | 2003-11-06 | 2008-02-12 | Advanced Cardiovascular Systems, Inc. | Coatings for drug delivery devices having gradient of hydration and methods for fabricating thereof |
US9114198B2 (en) | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
US8192752B2 (en) | 2003-11-21 | 2012-06-05 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same |
US7560492B1 (en) | 2003-11-25 | 2009-07-14 | Advanced Cardiovascular Systems, Inc. | Polysulfone block copolymers as drug-eluting coating material |
US7807722B2 (en) * | 2003-11-26 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Biobeneficial coating compositions and methods of making and using thereof |
US7220816B2 (en) | 2003-12-16 | 2007-05-22 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same |
US7435788B2 (en) | 2003-12-19 | 2008-10-14 | Advanced Cardiovascular Systems, Inc. | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
US8309112B2 (en) * | 2003-12-24 | 2012-11-13 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
US8685431B2 (en) | 2004-03-16 | 2014-04-01 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same |
US8551512B2 (en) | 2004-03-22 | 2013-10-08 | Advanced Cardiovascular Systems, Inc. | Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS |
US8778014B1 (en) | 2004-03-31 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Coatings for preventing balloon damage to polymer coated stents |
US7820732B2 (en) | 2004-04-30 | 2010-10-26 | Advanced Cardiovascular Systems, Inc. | Methods for modulating thermal and mechanical properties of coatings on implantable devices |
US8293890B2 (en) | 2004-04-30 | 2012-10-23 | Advanced Cardiovascular Systems, Inc. | Hyaluronic acid based copolymers |
US9561309B2 (en) | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
US7563780B1 (en) | 2004-06-18 | 2009-07-21 | Advanced Cardiovascular Systems, Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US20050287184A1 (en) | 2004-06-29 | 2005-12-29 | Hossainy Syed F A | Drug-delivery stent formulations for restenosis and vulnerable plaque |
US7494665B1 (en) | 2004-07-30 | 2009-02-24 | Advanced Cardiovascular Systems, Inc. | Polymers containing siloxane monomers |
US8357391B2 (en) | 2004-07-30 | 2013-01-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages |
US7311980B1 (en) | 2004-08-02 | 2007-12-25 | Advanced Cardiovascular Systems, Inc. | Polyactive/polylactic acid coatings for an implantable device |
US7648727B2 (en) | 2004-08-26 | 2010-01-19 | Advanced Cardiovascular Systems, Inc. | Methods for manufacturing a coated stent-balloon assembly |
US7244443B2 (en) | 2004-08-31 | 2007-07-17 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrophilic monomers |
US8110211B2 (en) | 2004-09-22 | 2012-02-07 | Advanced Cardiovascular Systems, Inc. | Medicated coatings for implantable medical devices including polyacrylates |
US7166680B2 (en) | 2004-10-06 | 2007-01-23 | Advanced Cardiovascular Systems, Inc. | Blends of poly(ester amide) polymers |
CA2584510C (en) * | 2004-10-25 | 2013-05-28 | Intezyne Technologies, Incorporated | Heterobifunctional poly(ethylene glycol) and uses thereof |
US8603634B2 (en) | 2004-10-27 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | End-capped poly(ester amide) copolymers |
US7390497B2 (en) | 2004-10-29 | 2008-06-24 | Advanced Cardiovascular Systems, Inc. | Poly(ester amide) filler blends for modulation of coating properties |
US7481835B1 (en) | 2004-10-29 | 2009-01-27 | Advanced Cardiovascular Systems, Inc. | Encapsulated covered stent |
US7214759B2 (en) | 2004-11-24 | 2007-05-08 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same |
US8609123B2 (en) | 2004-11-29 | 2013-12-17 | Advanced Cardiovascular Systems, Inc. | Derivatized poly(ester amide) as a biobeneficial coating |
US7588642B1 (en) | 2004-11-29 | 2009-09-15 | Advanced Cardiovascular Systems, Inc. | Abluminal stent coating apparatus and method using a brush assembly |
US7892592B1 (en) | 2004-11-30 | 2011-02-22 | Advanced Cardiovascular Systems, Inc. | Coating abluminal surfaces of stents and other implantable medical devices |
US7604818B2 (en) | 2004-12-22 | 2009-10-20 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrocarbon monomers |
US7419504B2 (en) | 2004-12-27 | 2008-09-02 | Advanced Cardiovascular Systems, Inc. | Poly(ester amide) block copolymers |
US8007775B2 (en) | 2004-12-30 | 2011-08-30 | Advanced Cardiovascular Systems, Inc. | Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same |
US7202325B2 (en) | 2005-01-14 | 2007-04-10 | Advanced Cardiovascular Systems, Inc. | Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles |
US7795467B1 (en) | 2005-04-26 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial polyurethanes for use in medical devices |
US8778375B2 (en) | 2005-04-29 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Amorphous poly(D,L-lactide) coating |
US7823533B2 (en) | 2005-06-30 | 2010-11-02 | Advanced Cardiovascular Systems, Inc. | Stent fixture and method for reducing coating defects |
US8021676B2 (en) | 2005-07-08 | 2011-09-20 | Advanced Cardiovascular Systems, Inc. | Functionalized chemically inert polymers for coatings |
US7785647B2 (en) | 2005-07-25 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Methods of providing antioxidants to a drug containing product |
US7735449B1 (en) | 2005-07-28 | 2010-06-15 | Advanced Cardiovascular Systems, Inc. | Stent fixture having rounded support structures and method for use thereof |
US7976891B1 (en) | 2005-12-16 | 2011-07-12 | Advanced Cardiovascular Systems, Inc. | Abluminal stent coating apparatus and method of using focused acoustic energy |
US7591841B2 (en) | 2005-12-16 | 2009-09-22 | Advanced Cardiovascular Systems, Inc. | Implantable devices for accelerated healing |
US7638156B1 (en) | 2005-12-19 | 2009-12-29 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for selectively coating a medical article |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US20070196428A1 (en) | 2006-02-17 | 2007-08-23 | Thierry Glauser | Nitric oxide generating medical devices |
US7601383B2 (en) | 2006-02-28 | 2009-10-13 | Advanced Cardiovascular Systems, Inc. | Coating construct containing poly (vinyl alcohol) |
US7713637B2 (en) | 2006-03-03 | 2010-05-11 | Advanced Cardiovascular Systems, Inc. | Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer |
US8212083B2 (en) | 2006-04-27 | 2012-07-03 | Intezyne Technologies, Inc. | Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof |
US8069814B2 (en) | 2006-05-04 | 2011-12-06 | Advanced Cardiovascular Systems, Inc. | Stent support devices |
US7985441B1 (en) | 2006-05-04 | 2011-07-26 | Yiwen Tang | Purification of polymers for coating applications |
US8304012B2 (en) | 2006-05-04 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Method for drying a stent |
US7775178B2 (en) | 2006-05-26 | 2010-08-17 | Advanced Cardiovascular Systems, Inc. | Stent coating apparatus and method |
US8568764B2 (en) | 2006-05-31 | 2013-10-29 | Advanced Cardiovascular Systems, Inc. | Methods of forming coating layers for medical devices utilizing flash vaporization |
US9561351B2 (en) | 2006-05-31 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Drug delivery spiral coil construct |
US8703167B2 (en) | 2006-06-05 | 2014-04-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug |
US8778376B2 (en) | 2006-06-09 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating |
US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US8114150B2 (en) | 2006-06-14 | 2012-02-14 | Advanced Cardiovascular Systems, Inc. | RGD peptide attached to bioabsorbable stents |
US8048448B2 (en) | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
US9028859B2 (en) | 2006-07-07 | 2015-05-12 | Advanced Cardiovascular Systems, Inc. | Phase-separated block copolymer coatings for implantable medical devices |
US8685430B1 (en) | 2006-07-14 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Tailored aliphatic polyesters for stent coatings |
US8703169B1 (en) | 2006-08-15 | 2014-04-22 | Abbott Cardiovascular Systems Inc. | Implantable device having a coating comprising carrageenan and a biostable polymer |
WO2008035229A2 (en) * | 2006-09-22 | 2008-03-27 | Labopharm, Inc. | Compositions and methods for ph targeted drug delivery |
US8597673B2 (en) | 2006-12-13 | 2013-12-03 | Advanced Cardiovascular Systems, Inc. | Coating of fast absorption or dissolution |
US8147769B1 (en) | 2007-05-16 | 2012-04-03 | Abbott Cardiovascular Systems Inc. | Stent and delivery system with reduced chemical degradation |
US9056155B1 (en) | 2007-05-29 | 2015-06-16 | Abbott Cardiovascular Systems Inc. | Coatings having an elastic primer layer |
WO2008151019A1 (en) * | 2007-05-30 | 2008-12-11 | University Of Florida Research Foundation, Inc. | Extended release of bioactive molecules from silicone hydrogels |
US8048441B2 (en) | 2007-06-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Nanobead releasing medical devices |
US8109904B1 (en) | 2007-06-25 | 2012-02-07 | Abbott Cardiovascular Systems Inc. | Drug delivery medical devices |
US8980241B2 (en) * | 2008-05-02 | 2015-03-17 | University Of Tsukuba | Polymerized cyclic nitroxide radical compound and use thereof |
US8685433B2 (en) | 2010-03-31 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
CN103328038A (zh) | 2010-12-01 | 2013-09-25 | 史拜诺莫度雷森公司 | 向神经解剖结构直接递送药剂 |
JP5907418B2 (ja) * | 2011-03-25 | 2016-04-26 | 日油株式会社 | 水酸基含有アセタール化合物の製造方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05117359A (ja) * | 1990-12-08 | 1993-05-14 | Bayer Ag | 水−分散性、電解質−安定性ポリエーテルエステル−改質ポリウレタンイオノマー、その製法、およびペルフルオロアルキル基含有重合体との混合物中でのその使用 |
JPH06508831A (ja) * | 1991-06-28 | 1994-10-06 | ローン−プーラン・ロレ・ソシエテ・アノニム | ポリオキシエチレンとポリ乳酸のブロック共重合体を基とするナノ粒子 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
-
1996
- 1996-04-18 DE DE69624475T patent/DE69624475T2/de not_active Expired - Lifetime
- 1996-04-18 NZ NZ305471A patent/NZ305471A/en unknown
- 1996-04-18 SI SI9620067A patent/SI9620067A/sl not_active IP Right Cessation
- 1996-04-18 AU AU53468/96A patent/AU5346896A/en not_active Abandoned
- 1996-04-18 BR BR9608330-1A patent/BR9608330A/pt not_active IP Right Cessation
- 1996-04-18 WO PCT/JP1996/001057 patent/WO1996033233A1/ja active IP Right Grant
- 1996-04-18 CA CA002218495A patent/CA2218495A1/en not_active Abandoned
- 1996-04-18 RU RU97119062/04A patent/RU2169742C2/ru active
- 1996-04-18 HU HU9801633A patent/HUP9801633A3/hu unknown
- 1996-04-18 KR KR1019970707384A patent/KR19990007861A/ko active IP Right Grant
- 1996-04-18 EP EP96910195A patent/EP0822217B1/en not_active Expired - Lifetime
- 1996-04-18 CN CN96194818A patent/CN1085987C/zh not_active Expired - Lifetime
- 1996-04-18 AT AT96910195T patent/ATE226603T1/de not_active IP Right Cessation
- 1996-04-18 JP JP53161996A patent/JP3855279B2/ja not_active Expired - Lifetime
- 1996-04-18 US US08/930,898 patent/US5925720A/en not_active Expired - Lifetime
-
1997
- 1997-10-10 NO NO19974678A patent/NO314762B1/no not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05117359A (ja) * | 1990-12-08 | 1993-05-14 | Bayer Ag | 水−分散性、電解質−安定性ポリエーテルエステル−改質ポリウレタンイオノマー、その製法、およびペルフルオロアルキル基含有重合体との混合物中でのその使用 |
JPH06508831A (ja) * | 1991-06-28 | 1994-10-06 | ローン−プーラン・ロレ・ソシエテ・アノニム | ポリオキシエチレンとポリ乳酸のブロック共重合体を基とするナノ粒子 |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999018998A3 (en) * | 1997-10-09 | 1999-07-22 | Univ Liverpool | Delivery system |
WO2001055722A1 (fr) * | 2000-01-26 | 2001-08-02 | Kazunori Kataoka | Detection d'une cible biologique |
WO2001086301A1 (fr) * | 2000-05-11 | 2001-11-15 | Center For Advanced Science And Technology Incubation, Ltd. | Composition polymère pour former la surface d'un biocapteur |
US6927033B2 (en) | 2000-05-11 | 2005-08-09 | Toudai Tlo, Ltd. | Polymer composition for forming surface of biosensor |
JP2003026566A (ja) * | 2001-07-13 | 2003-01-29 | Nano Career Kk | 薬物含有高分子ミセルの凍結乾燥用組成物およびその凍結乾燥製剤 |
EP1939280A1 (en) | 2001-07-26 | 2008-07-02 | Transparent Inc. | Cultured cell construct which contains spheroids of cultured animal cells and the use thereof |
WO2003076933A1 (fr) * | 2002-03-11 | 2003-09-18 | Toudai Tlo, Ltd. | Surface en poly(ethylene oxyde) a structure de type pinceau presentant une densite elevee |
US7214500B2 (en) | 2002-03-11 | 2007-05-08 | Toudai Tlo, Ltd. | Brush-like structured surface of poly(ethylene oxide) having elevated density |
WO2005073370A1 (ja) * | 2004-01-31 | 2005-08-11 | Transparent Inc. | 酵素複合体 |
JPWO2006095668A1 (ja) * | 2005-03-09 | 2008-08-14 | 東レ株式会社 | 微粒子および医薬品組成物 |
WO2006095668A1 (ja) * | 2005-03-09 | 2006-09-14 | Toray Industries, Inc. | 微粒子および医薬品組成物 |
EP2656840A1 (en) | 2005-06-09 | 2013-10-30 | NanoCarrier Co., Ltd. | Method for producing polymerized coordination compounds of platinum complex |
EP2474310A1 (en) | 2005-06-09 | 2012-07-11 | NanoCarrier Co., Ltd. | Method for producing polymerized coordination compounds of platinum complex |
US8592385B2 (en) | 2006-03-01 | 2013-11-26 | The University Of Tokyo | Polymer micelle complex including nucleic acid |
WO2007102608A1 (ja) * | 2006-03-06 | 2007-09-13 | Nanocarrier Co., Ltd. | 疎水性化合物の安定化剤 |
JPWO2007102608A1 (ja) * | 2006-03-06 | 2009-07-23 | ナノキャリア株式会社 | 疎水性化合物の安定化剤 |
WO2007126110A1 (ja) | 2006-04-24 | 2007-11-08 | Nanocarrier Co., Ltd. | 低分子薬物内包ポリマーミセルの製造方法 |
WO2008010341A1 (fr) | 2006-07-18 | 2008-01-24 | Nanocarrier Co., Ltd. | Polypeptide physiologiquement actif, micelle de polymère ayant une protéine enfermée dans celle-ci, et procédé d'obtention de la micelle de polymère |
US8153110B2 (en) | 2006-11-22 | 2012-04-10 | The University Of Tokyo | Environment-responding siRNA carrier using disulfide-cross-linked polymeric micelle |
WO2008062909A1 (fr) | 2006-11-22 | 2008-05-29 | The University Of Tokyo | Support d'arnsi sensible à l'environnement utilisant une micelle polymérique à pont disulfure |
US8075909B2 (en) | 2007-09-04 | 2011-12-13 | University Of Florida Research Foundation, Incorporated | Contact lens based bioactive agent delivery system |
WO2009133968A1 (ja) | 2008-04-30 | 2009-11-05 | 国立大学法人東京大学 | 電荷変換型三元系ポリプレックス |
WO2009157279A1 (ja) | 2008-06-24 | 2009-12-30 | ナノキャリア株式会社 | シスプラチン配位化合物の液体組成物 |
US8895076B2 (en) | 2008-06-24 | 2014-11-25 | Nanocarrier Co., Ltd. | Liquid composition of cisplatin coordination compound |
WO2009157561A1 (ja) | 2008-06-26 | 2009-12-30 | 独立行政法人科学技術振興機構 | Mri造影能を有する重合体-金属錯体複合体、並びにそれを用いたmri造影用及び/又は抗腫瘍用組成物 |
WO2011043980A1 (en) | 2009-10-07 | 2011-04-14 | Sanford Burnham Medical Research Institute | Methods and compositions related to clot-binding lipid compounds |
WO2011096558A1 (ja) | 2010-02-05 | 2011-08-11 | ナノキャリア株式会社 | 易崩壊型ポリマーミセル組成物 |
WO2011127405A1 (en) | 2010-04-08 | 2011-10-13 | Sanford-Burnham Medical Research Institute | Methods and compositions for enhanced delivery of compounds |
WO2011145745A1 (ja) | 2010-05-21 | 2011-11-24 | 独立行政法人科学技術振興機構 | 物質内包ベシクル及びその製造方法 |
EP3417934A1 (en) | 2010-05-21 | 2018-12-26 | Japan Science And Technology Agency | Substance-encapsulating vesicle and process for producing the same |
EP2626130A1 (en) | 2010-05-21 | 2013-08-14 | Japan Science And Technology Agency | Substance-encapsulating vesicle and process for producing the same |
WO2012005376A1 (ja) | 2010-07-09 | 2012-01-12 | 国立大学法人 東京大学 | 核酸送達用組成物及び担体組成物、それを用いた医薬組成物、並びに核酸送達方法 |
WO2012118778A1 (en) | 2011-02-28 | 2012-09-07 | Sanford-Burnham Medical Research Institute | Truncated car peptides and methods and compositions using truncated car peptides |
US10179801B2 (en) | 2011-08-26 | 2019-01-15 | Sanford-Burnham Medical Research Institute | Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides |
JP2013116933A (ja) * | 2011-12-01 | 2013-06-13 | Mitsubishi Rayon Co Ltd | ポリエステル(メタ)アクリレート、およびその製造方法 |
WO2014133172A1 (ja) | 2013-03-01 | 2014-09-04 | 独立行政法人科学技術振興機構 | 物質内包ベシクル及びその製造方法 |
WO2014185504A1 (ja) | 2013-05-17 | 2014-11-20 | ナノキャリア株式会社 | ポリマーミセル医薬組成物 |
WO2015016382A1 (en) | 2013-07-31 | 2015-02-05 | Ricoh Company, Limited | Imaging apparatus |
WO2015020026A1 (ja) | 2013-08-06 | 2015-02-12 | 独立行政法人科学技術振興機構 | 核酸内包高分子ミセル複合体及びその製造方法 |
US10046065B2 (en) | 2013-08-06 | 2018-08-14 | Japan Science And Technology Agency | Nucleic acid-encapsulating polymer micelle complex and method for producing same |
WO2015025983A1 (ja) | 2013-08-23 | 2015-02-26 | 国立大学法人東京大学 | 高分子ナノ粒子複合体、及びそれを含むmri造影用組成物 |
WO2015104739A1 (ja) | 2014-01-10 | 2015-07-16 | Jfeスチール株式会社 | 極厚肉油井管用ねじ継手 |
WO2015163195A1 (ja) * | 2014-04-25 | 2015-10-29 | 日産化学工業株式会社 | レジスト下層膜形成組成物及びそれを用いたレジストパターンの形成方法 |
US9910354B2 (en) | 2014-04-25 | 2018-03-06 | Nissan Chemical Industries, Ltd. | Resist underlayer film-forming composition and method for forming resist pattern using the same |
US10500246B2 (en) | 2015-06-25 | 2019-12-10 | Sanford Burnham Prebys Medical Discovery Institute | Compositions for delivery to and treatment of atherosclerotic plaques |
WO2018204392A1 (en) | 2017-05-02 | 2018-11-08 | Stanford Burnham Prebys Medical Discovery Institute | Tumor associated monocyte/macrophage binding peptide and methods of use thereof |
WO2020161602A1 (en) | 2019-02-04 | 2020-08-13 | University Of Tartu | Bi-specific extracellular matrix binding peptides and methods of use thereof |
WO2023068347A1 (ja) * | 2021-10-22 | 2023-04-27 | 株式会社クラレ | β-メチル-δ-バレロラクトン系重合体の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0822217B1 (en) | 2002-10-23 |
HUP9801633A3 (en) | 1999-03-01 |
US5925720A (en) | 1999-07-20 |
DE69624475T2 (de) | 2003-05-28 |
SI9620067A (sl) | 1998-06-30 |
NO314762B1 (no) | 2003-05-19 |
JP3855279B2 (ja) | 2006-12-06 |
BR9608330A (pt) | 1999-11-30 |
EP0822217A1 (en) | 1998-02-04 |
ATE226603T1 (de) | 2002-11-15 |
NO974678D0 (no) | 1997-10-10 |
RU2169742C2 (ru) | 2001-06-27 |
CN1085987C (zh) | 2002-06-05 |
KR19990007861A (ko) | 1999-01-25 |
DE69624475D1 (de) | 2002-11-28 |
NO974678L (no) | 1997-12-02 |
AU5346896A (en) | 1996-11-07 |
CN1187829A (zh) | 1998-07-15 |
MX9708025A (es) | 1998-07-31 |
NZ305471A (en) | 2000-02-28 |
CA2218495A1 (en) | 1996-10-24 |
HUP9801633A2 (hu) | 1998-11-30 |
EP0822217A4 (en) | 2000-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996033233A1 (fr) | Copolymeres en blocs heterotelecheliques et procede de production | |
RU2193574C2 (ru) | Полиоксиэтилен, имеющий сахар на одном конце и другую функциональную группу на другом конце, и способ его получения | |
KR960015447B1 (ko) | 의료용 생분해성 고분자 | |
JP3711288B2 (ja) | 両末端に官能基を有するブロックポリマー | |
US7259224B2 (en) | Hydrolytically degradable polymers and hydrogels made therefrom | |
US20030023023A1 (en) | Hydrolytically degradable polymers and hydrogels made therefrom | |
Acemoglu et al. | Novel bioerodible poly (hydroxyalkylene carbonates) s: a versatile class of polymers for medical and pharmaceutical applications | |
EP2730604B1 (en) | Functionalized caprolactone monomers useful for making poly(ethylene oxide)-block-poly(ester) block copolymers | |
CN103298838A (zh) | pH敏感的透明质酸衍生物和其应用 | |
Zhang et al. | Synthesis and characterization of biodegradable amphiphilic PEG-grafted poly (DTC-co-CL) | |
WO2006124205A2 (en) | Hydrophilic polymers with pendant functional groups and method thereof | |
Lee et al. | Synthesis and degradation behaviors of PEO/PL/PEO tri-block copolymers | |
KR100288002B1 (ko) | 폴리엘락타이드와 폴리에틸렌옥사이드의 스타형 공중합체 | |
AU744832B2 (en) | Heterotelechelic block copolymers and process for preparing same | |
JP4084679B2 (ja) | ポリ(エチレンオキシド)誘導体およびその重合開始剤としての用途 | |
NZ502021A (en) | Heterotelechelic block copolymer and a polymeric micelle comprising the heterotelechelic block copolymer in an aqueous solvent | |
AU1010002A (en) | Polyoxyethylene having a sugar on one end and a different functional group on the other end, and a method for the production thereof | |
AU4265400A (en) | Polyoxyethylene having a sugar on one end and a different functional group on the other end, and a method for the production thereof | |
CN111671915A (zh) | 一种多聚姜黄素丁二酸酐大分子衍生物及其制备方法和应用 | |
JP2004315554A (ja) | 水酸基含有ポリマーの製法 | |
JPH07292086A (ja) | ラクトン化合物の開環重合によるポリエステル型マクロモノマーの製造方法 | |
MXPA98001148A (en) | Block polymer that has functional groups in its two extreme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96194818.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 305471 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 97-01919 Country of ref document: RO |
|
ENP | Entry into the national phase |
Ref document number: 2218495 Country of ref document: CA Ref document number: 2218495 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/008025 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970707384 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-3312 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996910195 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08930898 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1996910195 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1997-3312 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970707384 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996910195 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970707384 Country of ref document: KR |